Boston, MA -- (SBWIRE) -- 08/23/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Fairchild Semiconductor Intl Inc (NYSE:FCS), CYS Investments Inc(NYSE:CYS), EXCO Resources Inc (NYSE:XCO), Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR)
Fairchild Semiconductor Intl Inc (NYSE:FCS) shares gained 2.74% and closed at $12.36. the company on August 21 announced that Catherine P. Lego has joined the company's board of directors. Lego formed Lego Ventures, LLC in 1992 to consult with early-stage technology companies.
Additionally, Research analysts at Robert W. Baird decreased their target price on shares of Fairchild Semiconductor International from $20.00 to $15.00 in a report released on August 15. The firm currently has an “outperform” rating on the stock.
How Should Investors Trade FCS After The Recent Volatility? Get Free Report Here
CYS Investments Inc(NYSE:CYS) shares climbed 0.58% to $6.91. CYS’s stock was downgraded by equities researchers at Maxim Group from a “buy” rating to a “hold” rating in a research report issued on August 13. They currently have a $10.00 target price on the stock.
Additionally, the company announced financial results for the quarter ended June 30, 2013. GAAP net loss available to common shares was $402.3 million, or $2.32 per diluted common share. Core Earnings plus Drop Income of $63.4 million, or $0.37 per diluted common share.
How Should Investors Trade CYS After The Recent Volatility? Get Free Report Here
EXCO Resources Inc (NYSE:XCO) shares climbed 2.17% to $7.54. The company on August 5 announced second quarter results for 2013. Adjusted net income was $0.10 per diluted share for the second quarter 2013 compared with $0.05 per diluted share for the second quarter 2012. GAAP results were net income of $86 million, or $0.40 per diluted share, for the second quarter 2013 compared with a net loss of $496 million, or $2.32 per diluted share, for the second quarter 2012.
Is XCO A Good Buy After The Recent Price Movement? Find Out Here
Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) shares dropped 0.20% to $5.03. The company on August 22 announced the publication of the findings from the PRISM patient registry in PLOS ONE, an international, peer-reviewed, open-access medical journal. PRISM was the largest registry ever conducted to further understand prevalence and impact of pseudobulbar affect (PBA) in the United States.
Additionally, the company on August 14 announced that it has entered into a settlement agreement with Sandoz, Inc. to resolve pending patent litigation in response to Sandoz's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA capsules.
Is AVNR A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)